Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults
NCT ID: NCT05517122
Last Updated: 2025-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
68 participants
INTERVENTIONAL
2022-07-12
2022-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NAD Supplementation Study
NCT03310034
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
NCT06882096
Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)
NCT03707652
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)
NCT06005350
Measurement of NAD+ Synthesis in Human Skeletal Muscle
NCT04905446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nicotinamide (NAM)
Nicotinamide (NAM)
500 mg a day
Nicotinamide Riboside (NR)
Nicotinamide Riboside (NR)
1000 mg a day
Nicotinamide Mono Nucleotide (NMN)
Nicotinamide Mono Nucleotide (NMN)
1000 mg a day
Microcrystalline cellulose
Microcrystalline cellulose
500 mg a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide (NAM)
500 mg a day
Nicotinamide Riboside (NR)
1000 mg a day
Nicotinamide Mono Nucleotide (NMN)
1000 mg a day
Microcrystalline cellulose
500 mg a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body mass index (BMI) between 18.5 to 27.0 kg/m².
3. Able to understand and to sign a written informed consent prior to study enrolment.
4. Willing and able to comply with the requirements for participation in this study.
Exclusion Criteria
2. Any chronic medical condition and/or history of significant medical condition, which in the opinion of the site physician/ investigator may risk participant wellbeing/ safety, impede participant compliance with study procedures or ability to complete the study and/ or could confound the primary objectives of the study.
3. Any acute illness or any recent medical intervention including vaccination within 14 days before the first dose of investigational product.
4. Female participants who are pregnant or intending to become pregnant, lactating and/or breastfeeding. Women of childbearing potential who are not currently using medically effective forms of contraception.
5. Use of prescription drugs known to potentially interact with NAD precursors within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
6. Use of multivitamin/ multimineral supplements, NAD+ precursor supplementation (e.g., niacin, nicotinic acid or niacinamide), L-tryptophan supplementation and/ or any over-the- counter (OTC) medication promoting "healthy aging" or "anti-aging" or "longevity" up to 30 days before first dose of investigational product.
7. On a self-restricted diet, controlled diet or special therapeutic diet up to 30 days before first dose of investigational product.
8. Average alcohol consumption greater than 2 standard drinks per day over a week for males, and greater than 1 standard drink per day over a week for females. One standard drink contains 10-12 g of ethanol. Examples of standard drinks are one beer can (300 ml), one glass of wine (100 ml) or one glass of schnaps (30 ml).
9. Current smoker (e.g., cigarette, tobacco, cannabis) who exceeds 5 cigarettes per week.
10. Performing shift work or trans-meridian travel greater than two time zones within 14 days prior to the first dose of investigational product.
11. Currently participating in another research study.
12. Family or hierarchical relationships with the Clinical Innovation Lab (CIL) team.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Société des Produits Nestlé (SPN)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nestlé Clinical Innovation Lab
Lausanne, Canton of Vaud, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2201NR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.